PolyNovo Limited
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CALZF research report →
Companypolynovo.com
PolyNovo Limited develops medical devices in the United States, Australia, New Zealand, the United Kingdom, Ireland, Singapore, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, which is used in a fully debrided clean surgical wound to physiologically close the wound. It is also developing hernia devices for hernia repair and tissue reinforcement products; NovoSorb Dermal Beta Cell Implant to host pancreatic islets in the skin; and NovoSorb drug elution depots.
- CEO
- Bruce Peatey
- IPO
- 2021
- Employees
- 282
- HQ
- Port Melbourne, VIC, AU
Price Chart
Valuation
- Market Cap
- $529.35M
- P/E
- 80.41
- P/S
- 5.76
- P/B
- 9.55
- EV/EBITDA
- 111.92
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 32.31%
- Op Margin
- 1.98%
- Net Margin
- 7.16%
- ROE
- 11.87%
- ROIC
- 2.64%
Growth & Income
- Revenue
- $127.24M · 23.31%
- Net Income
- $13.21M · 151.17%
- EPS
- $0.02 · 151.32%
- Op Income
- $4.48M
- FCF YoY
- -1471.88%
Performance & Tape
- 52W High
- $1.02
- 52W Low
- $0.55
- 50D MA
- $0.69
- 200D MA
- $0.77
- Beta
- 1.27
- Avg Volume
- 1.18K
Get TickerSpark's AI analysis on CALZF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our CALZF Coverage
We haven't published any research on CALZF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CALZF Report →